Clinical trials for Classic Hodgkin lymphoma
35 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT07275216Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentCity of Hope Medical Center · PI: Matthew Mei
- RECRUITINGPhase 2NCT07209059PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin LymphomaNational Research Center for Hematology, Russia · PI: Evgeny E Zvonkov, MD, PhD
- RECRUITINGPhase 2NCT06984146Nivo40-AVD for Advanced Classic Hodgkin LymphomaNational Medical Research Radiological Centre of the Ministry of Health of Russia · PI: Andrey Kaprin
- RECRUITINGPhase 2NCT06745076Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin LymphomaUniversity of Washington · PI: Ryan Lynch, MD
- RECRUITINGPHASE1, PHASE2NCT06642792A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin LymphomaAkeso · PI: Wenting Li, MD
- RECRUITINGPhase 2NCT06377540MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin LymphomaMasonic Cancer Center, University of Minnesota
- RECRUITINGPhase 2NCT07234487Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHLSt. Petersburg State Pavlov Medical University · PI: Natalia Mikhailova, MD, PhD
- RECRUITINGPhase 2NCT06812858PD-1 Inhibitors Maintenance for cHL Post-autoHCTSt. Petersburg State Pavlov Medical University · PI: Natalia Mikhailova, MD
- RECRUITINGPhase 4NCT06831370A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in IndiaTakeda
- ACTIVE NOT RECRUITINGPhase 2NCT06164275Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin LymphomaNorthwestern University · PI: Jane N Winter, MD
- RECRUITINGPhase 3NCT06170489A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)Shanghai Junshi Bioscience Co., Ltd.
- ACTIVE NOT RECRUITINGPhase 2NCT05922904PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin LymphomaM.D. Anderson Cancer Center · PI: Hun Lee, MD
- RECRUITINGPhase 2NCT06190067Azacitidine Plus PD-1 Therapy for R/R Hodgkin LymphomaNavy General Hospital, Beijing · PI: Liren Qian, PhD
- RECRUITINGPhase 2NCT05949931Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin LymphomaSun Yat-sen University
- RECRUITINGNCT05705531A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin LymphomaChildren's Oncology Group · PI: Robert J Hayashi
- RECRUITINGPhase 2NCT05821088Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell LymphomaDavid Bond, MD · PI: David A Bond, MD
- RECRUITINGPhase 2NCT05723055Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin LymphomaUniversity of Utah · PI: Harsh Shah, MD
- RECRUITINGPhase 2NCT05180097Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin LymphomaCanadian Cancer Trials Group · PI: Kerry Savage
- ACTIVE NOT RECRUITINGPhase 2NCT04788043Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin LymphomaStanford University · PI: Ranjana H Advani, MD
- RECRUITINGPhase 2NCT05039073Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint InhibitorsEmory University · PI: Kristie Blum, MD
- ACTIVE NOT RECRUITINGPhase 1NCT05162976CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or RelapsedCity of Hope Medical Center · PI: Matthew Mei, MD
- RECRUITINGPhase 2NCT04561206Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin LymphomaCity of Hope Medical Center · PI: Alex F Herrera
- ACTIVE NOT RECRUITINGPhase 2NCT04938232Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHLDana-Farber Cancer Institute · PI: Reid W Merryman, MD
- ACTIVE NOT RECRUITINGPhase 3NCT03907488Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaNational Cancer Institute (NCI) · PI: Alex F Herrera
- ACTIVE NOT RECRUITINGPhase 2NCT03755804Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17St. Jude Children's Research Hospital · PI: Matthew Ehrhardt, MD, MS
- ACTIVE NOT RECRUITINGPhase 2NCT03712202Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin LymphomaCity of Hope Medical Center · PI: Alex F Herrera
- RECRUITINGPHASE1, PHASE2NCT03681561Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin LymphomaVeronika Bachanova · PI: Veronkia Bachanova
- ACTIVE NOT RECRUITINGPhase 2NCT03407144Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)Merck Sharp & Dohme LLC · PI: Medical Director
- ACTIVE NOT RECRUITINGPhase 2NCT03233347Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin LymphomaAcademic and Community Cancer Research United · PI: Steven I Park
- ACTIVE NOT RECRUITINGPhase 1NCT03150329Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.City of Hope Medical Center · PI: Alex F Herrera
- ACTIVE NOT RECRUITINGPhase 2NCT03057795Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin LymphomaCity of Hope Medical Center · PI: Alex Herrera
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03033914A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)Memorial Sloan Kettering Cancer Center · PI: Alison Moskowitz, MD
- ACTIVE NOT RECRUITINGPhase 2NCT02758717Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin LymphomaAcademic and Community Cancer Research United · PI: Bruce D Cheson
- ACTIVE NOT RECRUITINGPhase 3NCT02166463Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin LymphomaNational Cancer Institute (NCI) · PI: Sharon M Castellino
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT01896999Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin LymphomaNational Cancer Institute (NCI) · PI: Catherine S Diefenbach